Dunkin’ Donuts plans to roll out a croissant-doughnut hybrid in the U.S. next week, but the company says please don’t call it a “Cronut.”
The long wait is over. Shake Shack says it will open Nov. 4 at Ohio and Rush streets. [Entertainment]
CVS and Rite-Aid are part of a consortium of retailers, led by Wal-Mart, that’s developed a competing system, Forbes reports.
Capital New York reports that REQX Ventures has bought the Divvy parent, also acquiring CitiBike in New York and other fleets in the deal.
U.S. stocks ended mixed Monday as the price of oil slips and more disappointing news on the global economy emerges.
A Nike Training Club shop has opened at Macy’s on State Street and is coming to Macy’s at Oakbrook Center, Crain’s reports.
Northern Indiana officials are celebrating the start of direct air service between South Bend International Airport and Newark Liberty International Airport in New Jersey.
Twitter’s 3rd quarter revenue outpaced expectations, but investors concerned about user growth and holiday-quarter sales clipped the company’s stock.
The company’s Toyota and Lexus brands top the survey, and its Scion brand is in the Top 10.
Once a hulking symbol of American excess, sport utility vehicles are quickly becoming the world’s favorite way to get around.
Nutek Disposables has issued a nationwide voluntary product recall of baby wipes because some packages may contain bacteria.
Honeywell says there’s no evidence that a weekend leak of a compound used in uranium enrichment at its southern Illinois plant escaped that building.
Sam’s Club is trying to attract small-business owners by offering health care, payroll and legal services, Entrepreneur reports.
Chiquita has agreed to sell itself to two Brazilian companies for about $681 million, just days after shareholders rejected a merger with Fyffes.
Merck’s income fell mostly because of large costs tied to acquisitions and divestitures. But the drugmaker’s adjusted earnings topped expectations.
The Canadian drugmaker Valeant said it would be willing to raise its takeover bid for Allergan by almost 12 percent.